Joshua J. Meeks, MD, PhD, discusses effectively implementing recent therapeutic advances across the disease continuum of bladder cancer.
Joshua J. Meeks, MD, PhD
Advertisement
Articles by Joshua J. Meeks, MD, PhD
Joshua J. Meeks, MD, PhD, assistant professor of urology, Northwestern University Feinberg School of Medicine, discusses the importance of p53 and Rb1 in bladder cancer.
Joshua J. Meeks, MD, PhD, assistant professor of urology, Northwestern University Feinberg School of Medicine, discusses the mutations associated with T1 progression in bladder cancer.
Advertisement
Latest Updated Articles
Dr. Meeks on Mutations Associated With T1 Progression in Bladder CancerPublished: November 6th 2018 | Updated:
Dr. Meeks on the Importance of p53 and Rb1 in Bladder CancerPublished: January 25th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
GLORA-4 Set to Evaluate Lisaftoclax Plus Azacitidine in Higher-Risk MDS in First-of-Its-Kind Study
5